Blood and Lymphatic Cancer: Targets and Therapy

The antibody drug conjugate, belantamab-mafodotin, in the treatment of multiple myeloma: A comprehensive review

Leukemia & Lymphoma

Are we maintaining minimal residual disease in myeloma?

Clinical Cancer Research

Population pharmacokinetics of orvacabtagene autoleucel, an autologous BCMA-directed chimeric antigen receptor T-cell product, in patients with relapsed/refractory multiple myeloma

Presse Medicale

Updates on mechanisms of disease progression in precursor myeloma: Monoclonal gammopathy of undermined significance and smoldering myeloma

Journal of Patient-Reported Outcomes

Trajectory, interactions, and predictors of higher symptom burden during induction therapy for multiple myeloma

Blood Advances

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma

Cancer Metastasis Reviews

CAR T-cell therapy to treat multiple myeloma: Current state and future directions

Journal of Cancer Policy

Financial conflicts among physician speakers at the April 12, 2024, Oncology Drug Advisory Meeting: Who decided that MRD can be a novel regulatory endpoint in myeloma?

Cancer Medicine

Comparison of time to next treatment or death between front-line daratumumab, lenalidomide, and dexamethasone (DRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) among transplant-ineligible patients with multiple myeloma

Pharmaceuticals

Unravelling transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: The CARINAE study